Transcript

Hello everybody. We get started. So my name is Andrew Chess and I'm lecturing today and um replacing Eric Lander for the day. He had to be out of town. Something he could not reschedule. He really tries to arrange his very busy schedule so that he is here but this was something that um he could not be rearranged anyway. So I'm a professor at Harvard Medical School. Um but I have a long history here at MIT including uh being on faculty here for a number of years and I used to teach um undergraduates and even going back further than that I actually took this class um it was called 701 without an extra number at that time.

Um now it's what 7012 or 70312 anyway. So it was called 701 and it was also an extremely interesting introduction to biology back then. It was sometime over 20 years ago. I'm not sure exactly how many years I kind of stopped uh counting at 20. So when when Eric called me when Professor Lander called me up to ask me to give this lecture, I talked to him for a while and I agreed to do it. And then I was thinking about what to present and I went over the material that he's presented to you earlier this week and and I discussed with him some of the things that he likes to do for the third lecture on neurobiology.

And I also thought about some of the things that I would like to do. And so one of the things that that occurred to me so it's probably occurred to you from hearing Eric talk about neurobiology earlier this week that he is very enthusiastic about the subject. He always talks about it as being one of the driving forces that led him to enter biology from the um realm of mathematics where he started his academic career. Anyway, so he's always talked to me in the years I've known him about how he loves neurobiology. And I was thinking about it and it's in some ways kind of ironic that Eric loves neurobiology so much because in some ways he's been a big troublemaker for neurobiology.

Let me explain. So Eric, Professor Lander is of course as you all know was an instrumental driving force behind the sequencing of the human genome. Before all those efforts over the last decade, people used to go around, biologists would go around to each other and they would talk and they would say there are around a 100,000 genes in the human genome or 100,000 genes in a mouse genome. Malian genomes have around 100,000 genes. Sometimes some people would say 90,000 genes, sometimes they would say 110,000 genes, but generally it was at around 100,000 genes. And everybody was comfortable with that.

In fact, right around the turn of the century when the stock market was going way up, the internet bubble and biotech bubble and everything, estimates of the number of genes in the human genome actually went higher also. They went up as high as 120, 150,000. And this I think was because various companies were competing to have the most genes on their kind of microarray or whatever they were selling. Um they want to say we have the most and so they kept saying more. The academic scientists usually still stayed around 100,000 in terms of their thinking. Okay. The other thing that was very um of of a lot of use to neurobiologists in terms of them feeling that their problem of trying to figure out how the brain is set up is a is a tractable problem was that they thought there were going to be lots of genes available.

So there were 100,000 genes in the genome and around half of them people would say are probably brain specific. So there were a variety of pieces of evidence that people would think that a lot of the genes in the genome would be brain specific and that still remains the case. But as you know from Eric Landers and other people's work sequencing the human genome and mouse genome and other genomes now it looks like mammals now have only around 30 to 40,000 genes. Now if Eric told you a different number, listen to his number. What did he say? 2025. Okay. Anyway, so many fewer than a 100,000. Okay, a small number.

A fly is thought to only have around to have around 15,000 genes. So, so, so Lander is now saying that humans don't have that many more genes than flies. So, this presented a problem for neurobiologists because even if you have half of them brain specific, you still don't have nearly as many genes to play with to make the complex structure of the brain as you did when there were 100,000 genes in the genome. So, the the brain of course is an extremely complicated structure. They're thought to be um somewhere between a 100red billion and a trillion different neurons in the brain. Um and they also fall into many many different neural types.

And so the the developmental process now developmental biology is something that some of you will study in in future courses and you'll have had some introduction to here. That's how you get from an uh a single fertilized egg, a single cell to the complex organism. In the brain, it's particularly a difficult problem because you have so many different types of cells and so many cells. And each cell that makes all of these complex connections, a given neuron might connect to a thousand or a few thousand different other cells as a a normal normal process. So forming all these different kinds of neurons and wiring up is a very daunting problem.

So what I thought I would do today would be to focus on two examples where in each case starting with either one gene or a small number of genes you get a lot of complexity. So this would then allow the smaller number of total gene number in the in the human genome to allow a lot of different kinds of proteins and maybe provide some explanations for certain parts of the complexity of the brain. Now, by no means do I am I going to attempt to explain all of how the brain uh develops. That would take um well, at least one course, more more likely a few different courses to actually get a good appreciation of that.

But I'm going to go through a couple of very intriguing examples that are um approachable um at at at the level um of this class. Okay. So the standard way that we think about how genetic information gets um made into proteins is that there's DNA and then RNA and then proteins. I hope at this point in 701 this is all familiar to you. Good. Okay. So the DNA sequence gets transcribed into an RNA and then there's a splicing event which takes bits and pieces of the RNA, puts them together and then there's an area of the RNA that tells the ribosome to start making a protein and so you get the protein synthesis.

Everything is following from the blueprint that was in the DNA. So what I'm going to talk about today are two different examples. One of them involves alternative splicing and that will be cases where instead of there being a static always reproduced way of going from DNA to RNA to a protein that there are different um alternative splicing events that can occur and this can allow one gene to make multiple different protein products. And then I'm going to go over another um way that you can violate this central dogma, this DNA RNA protein um which is something called RNA editing. So as you might imagine from the common use usage of the word editing, by editing what we mean is that the RNA sequence itself is actually changed so that it no longer reflects the exact nucleotide sequence of the DNA.

This can also add diversity to the number of potential um encoded proteins. I want to make sure that I I'm going to talk about neural specific examples but I want to mention that these processes alternative splicing and RNA editing are used also by other parts of the developing animal not just by um and also in other plants and other organisms not just by um the brain um to generate diversity. So, so these are mechanisms that are are widely used, but some of the most striking examples, as you'll see from my lecture and then further reading that you might do in the future, some of the most striking examples come from the nervous system.

And that's not surprising given the complexity of the nervous system and the fact that there aren't so many genes out there ready to help with this um complexity. So, so the first I'll turn to alternative splicing. So first before getting into the extremely complex case that I'm going to focus on, I'm going to just briefly by way of introduction go over a standard alternative splicing scenario. Okay. So in in in a gene for which there's no alternative splicing if I draw the exxons as boxes and the introns as lines what winds up happening is you have the first exxon is spliced to the second one second to the third to the fourth and so what you wind up with is a messenger RNA.

So here's the messenger RNA which has been spliced from the from the primary transcript. The primary transcript of course reflects the actual structure of the the DNA in terms of sequence also because in the genomic DNA you'd also have areas that are going to be exxons and intron exxon intron exactly like this. So this is just a general example of alternative splicing I'm sorry of of um of regular splicing. So then alternative splicing would involve something like this. You'd have one two 3 a 3 B 4. So then what happens is you have normal splicing of from 1 to two and then two can either go to 3 A which will then go to four leaving 3B out or the alternative is that two can skip 3 A go to 3B which will then splice to four.

So this allows then two different messages to be formed. So the this 3A and 3B might encode a slightly different protein sequence and might then allow two distinct proteins with different functions. to be formed from one message. So this is an example a simple example general example of alternative splicing. So from one gene you have two proteins. The example that I'm going to focus on today, instead of going from one gene to two proteins, allows you to go from one gene to 38,000 different possibilities. It's actually 38,016 to be exact. And I'll explain to you why, but 38,000 will have occurred to you that this is larger than the number of genes that Eric Lander says are in the human genome.

It's certainly longer larger than the number of genes in the um fly genome. And this example I'm giving you is is from a single gene in the fruitfly. This one gene can come in 38,000 different forms. The gene is called Drosophila DSCAM. It's named for a human gene which was cloned first and characterized first which was called just plain DSCAM. What DSCAM stands for is Down syndrome cell adhesion molecule. And let me just explain briefly why it has this name. I don't think that this name is actually relevant so much to the biology and it's certainly not relevant to the alternative splicing because the human gene and the mouse gene neither of them have a lot of alternative splicing.

This is something that's particular to the fly. That's something I will return to later in the lecture. This name down syndrome cell adhesion molecule came about because this was cloned first from human and it's located on human chromosome 21. Chromosome 21 is normally present in two copies in every every individual. In individuals who wind up with three copies of chromosome 21 something called tricom 21. Tricom 21 causes Down syndrome which is a syndrome that that um has some brain um manifestations like mental retardation and also has a number of other problems associated with it. When the people who found this gene found it, they named it so they gave it the first part of its name.

The DS comes from Down syndrome. Cell adhesion molecule comes from the fact that this gene is similar in structure to a lot of known cell adhesion molecules that are um encoded by many many different loi in in the genome. And they initially thought that perhaps and and this and this gene is expressed in the brain. And they initially thought that perhaps having an extra copy a third copy of this gene might be what's causing a lot of the brain um phenotypes. Subsequent work has not further provided provided further evidence for that. So at this point what I would say is that it's the name of the gene is down syndrome cell adhesion molecule DSCAM.

It's on human chromosome 21. may play a role in Down syndrome, but there isn't besides the na the name is really the best evidence that it plays a role and just the fact that they named it that. Okay, so um but but in the fly this is an extremely interesting molecule because as I mentioned it can come in 38,000 different forms. Okay. So, as for why you would have a cell adhesion molecule in the brain, just want to mention briefly. So, Professor Lander went over with you the structure of of a neuron that neurons have cell bodies and axons and growth cones which allow them to get to wherever they're supposed to connect.

One of the types of molecules that allows an axon as it's growing, the growth cone, to lead an axon along a complex path, is to interact with various structures that that it encounters. And so cell adhesion molecule is one of the kinds of molecules that can allow the growth cone and then the rest of the axon to interact with various other cells or other extracellular substrates, proteins that have been deposited by other kinds of cells as they make their way um and make the appropriate connections in the brain. So cell adhesion molecules are one of the mechanisms. There also mechanisms that allow um cells to respond to to um to gradients of chemical signaling messengers.

Question. Yes. Oh, I'm sorry. Can you explain what a growth is? Oh, I'm sorry. That was not covered. Okay. So, um a neuron has a cell body with a nucleus and all the other stuff that's in regular cells that you learned about. It then has an axon which then allows it to connect and this connection could be very far away. In the case of for example a motor neuron in the spinal cord that's innervating a muscle in the foot that that that single cell would would have its cell body in the spinal cord and its axon go all the way out to the foot. Okay, so these ax and that's just an example of one very long neuron.

Some of them are very long, some of them are shorter. So this is the axon. At the tip of the axon is this thing which looks sort of like uh my son's mitten for when it's cold outside. But this is the growth cone. And basically what's going on is as as the axon is growing out in this direction, it's feeling its way and and and there might be cell adhesion molecules on these different protrusions that if they attach really well, it might like let's say that this area over here is stickier for the this particular growth cone than this area over here. Then this growth axon is more likely to grow in that direction.

Okay, so cell adhesion molecules are well known to play important roles in axon guidance, how axons grow in different directions. So I'll tell you now about the structure of the DSCAM gene and that will give some insight into how the 38,000 different forms might be used because they're going to provide different kinds of stickiness. Let me explain. So this is a a drawing of the genomic organization of DSCAM that allows the extensive alternative splicing. So this diagram is similar to the diagram that I drew by hand for um the more simple cases. But basically in dscam what you start out with is exxon one gets spliced to exxon 2 gets splice to exxon 3 and then when you reach exxon 4 there are 12 distinct possibilities and only one of the 12 is chosen.

In this case, the diagram shows it choosing, I don't know, the ninth one perhaps. Then Exxon 5 is regular. So that always gets included. Then Exxon 6, there are 48 distinct choices. And again, only one is chosen. Here in this example, this one has been chosen at the expense of all of these other ones. Exxon 7 and 8 are normal. Then Exxon 9, there are 33 choices. Exxon 17, there are two choices. And if you multiply 2x 33x 48 x 12, you wind up with 38,16. There's evidence from a number of different types of studies, including cloning and sequencing, lots of different messenger RNAs that are already spliced, that basically almost all of these forms can be made.

So what this structure allows is for there to be diversity generated in important areas of the cell adhesion part of this molecule. So The DSCAM molecule starts out with a number of of domains which are called imunoglobulin like domains. Imunogloabbulbin domains are named for imogloabbulins which is another name for antibodies. Antibodies help you fight infection. I don't know if that's been covered. Has it been covered? Yes. Um, and the particular fold that they form allows recognition of foreign antigens and it also allows stickiness of molecules in general. So, cell adhesion molecules often have these imogloabbulin domains.

The DSCAM starts out with um from the N terminus towards the C terminal. starts out the first nine domains are these IG type domains that's then followed by another kind of domain called a fibonnectin type domain which that's not important all of the diversity is in this nine um imaglabbulin domains the exxon 4 diversity allows diversity of the second of the nine the exxon 6 alter Alternative splicing affects the third out of the nine imunogloabbulin folds and the exxon 9 diversity affects the seventh. So so of these nine domains of of the imogloabulin folds that allow for different kinds of stickiness.

A lot of them are the same. One um one is the same. Four, five and six are the same. and eight and nine are the same. But 2, three, and seven have these differences which are encoded by this striking kind of genomic structure and alternative splicing. So how is this diversity used? So the early models for how DSAM diversity would be used stipulated that individual different kinds of neurons might express vastly reduced subsets out of the 38,000. So let's say that one particular neuron type of which there might be many different neurons might express maybe 10 out of the 38,000 or even one out of 38,000.

These were the different kinds of models that were tossed around by people who were thinking about this this problem. But then it people started to study it and what turned out to be the case is that looks like every kind of neuron population at first approximation expresses almost all of the different forms. Okay, so these are wrong these models and and each different neuron type expresses a slightly different repertoire but at first approximation over 10 or 20,000 forms are possible for each different neuron neuron type. So that then caused people to scratch their heads and wonder well how is this used then?

How is this used to make different kinds of neurons different from one another or any anything in the in the function of them? So this the answer to this question has emerged in part from analyses of individual single cells. So it turns out that an individual cell and I'm using the word cell and neuron interchangeably because neurons are cells and and um cells are not all cells are neurons but all neurons are cells. So for one cell or one neuron it makes somewhere in the range of 10 of 10 to uh 50 forms. These are randomly chosen apparently from the data that's available from the tens of thousands of forms that are possible.

So you can imagine that two neighboring cells that are otherwise identical that each are picking say let's say 10 to make it easy 10 different forms of DSCAM are going to wind up with very different repertoires of DSCM than an adjacent cell. So what this allows is each individual cell to have a unique identity. The whole idea that individual neurons might need to have a unique identity actually is is a new concept that's really been enlightened by this this this molecule because the way that people used to think of neurons is that they would wind up with unique identities based on the on the connections or the or experience what what they were exposed to in terms of different stimuli.

But what this indicates is that from the splicing of of an individual gene and the fact that each time this gene gets spliced, you can wind up with a different form that at any given time each cell will have a unique set of of messenger RNAs and therefore proteins encoding this DSCAM gene. Okay, so I mentioned earlier that the human DSCAM does not have alternative splicing. We all like to think of ourselves, humans and other mammals as having brains that are on the level of complexity at least on par with a fly. And so it's um odd to think of all all this complexity that's there for for flies and and other other insects, but why is it not there for humans?

Well, it turns out that there are other kinds of genes that are um that that do have extensive alternative splicing in mammals. So, one of them is um called nurexins. These are genes that are involved in synapse, how the different kinds of cells communicate with each other at the interface. There are genes called um protoadhirins. And there are also other kinds of genes that all have um extensive alternative splicing in mammals. Interestingly, these genes tend not to have extensive alternative splicing in flies. It's as if in each lineage certain genes have been chosen to get a lot of diversity by this mechanism of alternative splicing and other genes are left with their just standard single function where it's one gene, one RNA, one protein.

Okay. So I'm going to switch now to the second example which is RNA editing. So as I mentioned earlier, RNA editing involves an actual change in the RNA sequence so that it no longer reflects the exact DNA sequence. Now this is different than splicing. Splicing takes different pieces of RNA and splices them together, leaving out intervening sequences or introns. But in RNA editing, you actually change the nucleotide sequence so that um it no longer is identical to the DNA. This is used um in a number of parts of the brain. Most of the examples are brain specific. There are some non-brain specific parts.

Most of the time the editing event changes an adenosine or an A in the ACGT nomenclature into an innocine. This is read differently by the ribosome than than the adenosine. So this leads for example in an important kind of channel called a glutamate receptor and the specific subtype that I'm talking about is something called an ampa glutamate receptor. That's for a chemical lian that activates this particular kind of glutamate receptor. This leads to an important change of a glutamine to an arginine in the protein. So let me draw a quick diagram of what the um of what the uh protein looks like.

So we can see what the importance of this glutamine to arginine switch in this glutamate receptor is so in the absence of detailed structural information about different kinds of neurotransmitter receptors people often draw a diagram like this where this is the outside of the cell. This is the inside of the cell. This represents the cell membrane. And they draw here's the the the amot terminus and then they draw transmembrane portion. And this is what's called a re-entrant loop. It doesn't quite pass through the membrane, but then the passes through the membrane again. And then here's the caroxy terminus.

The glutamine to arginine change is here. It's in this area which inv is involved in making the pore. So the pore of the channel has this change. glutamine to arginine change. This vastly changes the properties of the channel a channel that doesn't undergo this editing event. So, so, so let me just state that for the um the glue R2 ampceptor which is one of four different genes. It is 99% edited in adults. So n or over 99% of the time this um adenosine is made into an innocine which leads to a glutamine becoming an arginine in the protein. What this does to the channel is it is it changes its permeability.

So so this is a kind of channel that is mostly designed to let sodium in but if it doesn't get edited if the glutamine is there it also lets calcium in. So whether or not calcium gets into the cell is very important because they're both both sodium and and calcium are are cat ions and can lead to membrane potential disturbances like you learned about earlier this week leading to an action potential. But calcium also has other effects on it can lead ultimately to the turning on and off of genes and phosphor phosphorilation of various proteins to other kinds of effects in the neuron. So it has to be regulated very tightly.

So these channels are designed to just let sodium through to be involved in the transmission of an action potential from the um from from one neuron to the next. So if you had a perturbation in in this process, you would then also let calcium calcium in because the glutamine containing channel lets calcium in. In fact, early in development, it's probably true that you don't edit 100% and you let a little bit of calcium in. And there are also other glutamate receptors that um are not part of the AMPA family but they're related and they're encoded by genes called so this is gluar 1 through 4 encodes AMP receptors a gene called glu 5 and six they have editing which is more regulated and by by regulated I mean that the editing is sometimes present and sometimes not.

So even within a given um uh neuron you might have some channels that have the glutamine and some channels that have the arginine. There are also other sites I've talked about the main site. This is the one that has the most profound impact on the function of the protein. There are also other sites in the molecule that are edited. So and and they also have important um but but but but slightly less prominent roles in in the regulation of of um of these channels. So what leads this gene to become edited? Why do most genes not become edited and this gene becomes edited? Well, people are starting to pursue that kind of um mechanisms.

And one of the mechanisms that's become very clear is that for example in the in the in the Q2R change in the pore where um the adenosine to innocine change in the messenger RNA that leads to the Q2R change in the pore. If you look at the the the exxon where that I'll I'll draw it as an A where that A is present. There's an area and then here's the intron of the intronic sequence which actually loops back and then allows base pairing to form between the messenger RNA and the intron. And then the enzymes that are involved in mediating this adenosine to innocine change recognize the base pairing of this short area and some sequence specificity to the R to the um RNA sequence that's around here.

It's not just any base pairing, but the base pairing is critical. And then the the enzymes which are called adenosine diaminases um can mediate this change of an adenosine to an innocine. So this gene has been selected to have parts of its intron in addition to allowing splicing to occur to actually be able to base pair and allow this editing function to happen. And so this this allows an individual gene then to make more than one um form of protein. Okay. One other example that I'll tell you about of RNA editing involves the serotonin system and involves um serotonin receptor which has RNA editing.

And this is a serotonin receptor whose name is serotonin receptor 2C. So it's often written as 5HT for five hydroxyryptamine 2C serotonin receptor. This receptor is a member of the G-proin coupled receptor super family. G-proin coupled receptors are seven transmembrane domain receptors. And the editing of the serotonin receptor occurs in the um second intracellular loop and affects the coupling to to G- protein. So the way that these G- protein coupled receptors did they do this right? G- protein couple receptors transduce the signal through a G- protein which often binds to the intracellular loops particularly the second loop and the editing event which changes adenosines to innocines there are actually a few of them in this region here a few different sites which can get changed that affects the efficiency of of the transduction when serotonin is pres present the transduction of a signal in inside the cell.

There are other serotonin receptors that are lian gated channels, but they don't appear to have the same kind of editing as this um uh serotonin receptor um that's of the groin coupled variety has. So I'll end with just one final note about this serotonin receptor which is that a drug called fluoxitine or prozac which did Eric go over that this year? Prozac? No. Okay. He mentioned so so it's mostly known as something which blocks re-uptake of serotonin. So it so one cell releases serotonin which is a neurotransmitter. Another cell responds to it. If you block the re-uptake, the neurotransmitter is present in the syninnapse for a longer amount of time leading to increased signaling.

Prozac is widely thought to have its main effect and that's probably is its main effect to just block the reuptake leading to increased serotonin signaling. Someone has studied the serotonin receptor in individuals who are taking Prozac versus individuals who are not taking Prozac. And what they found was that there were differences in the editing amount of editing of various sites in this key area in individuals taking Prozac versus individuals not taking Prozac and the direction of the difference whether it's switching from edited to unedited or or or back and it varies for the different sites.

the direction was the opposite of what was seen in a in a comparison of um brains of victims of of suicide versus brains of other accident uh victims. So it looks like Prozac is having an effect which is in the opposite effect to the skewing of editing that one sees in certain uh cases of depression. So I I I bring that example up because it's important to to know that that you know if you can impact on some of these subtle differences between different kinds of messages like whether it's edited or not or whether the splicing is more towards one kind of alternative splicing or another another kind of alternative splicing.

these might provide very interesting um pharmacologic targets for um for therapies um that might impact on a variety of different uh human diseases. So what I've hope to do is give you a sense of a couple of different examples where you can take a single gene and make more than one protein and this can lead to increases in the diversity of neurons and therefore increases in the complexity of the brain. Thank you. Are there questions?